Panel chair discusses latest updates to NCCN guidelines for bladder cancerFebruary 6th 2023
“A majority of patients that present with bladder cancer do not have muscle invasive disease. They have earlier stage, non-muscle invasive, and the NCCN guidelines have detailed guidance for providers about managing those patients,” said Thomas Flaig, MD.
Dr. Packiam discusses promise of pembrolizumab plus cabazitaxel/gemcitabine in urothelial carcinomaJuly 26th 2022
Study results presented at the 2022 AUA Annual Meeting showed that pembrolizumab plus cabazitaxel and gemcitabine had promising early efficacy in heavily pretreated patients with high-risk non–muscle invasive urothelial carcinoma.
Dr. Galsky discusses combo of nivolumab plus trastuzumab deruxtecan in urothelial carcinomaMay 9th 2022
In the DS8201-A-U105 trial, the combination of the antibody-drug conjugate trastuzumab deruxtecan and the immunotherapy nivolumab demonstrated antitumor activity in patients with HER2-expressing urothelial carcinoma.
Expert explains significance of FDA approval of 177Lu-PSMA-617 for mCRPCApril 11th 2022
Richard Wahl, MD, president of the Society of Nuclear Medicine and Molecular Imaging, highlights the approval of 177Lu-PSMA-617 (Lu 177 vipivotide tetraxetan) as the first targeted radioligand therapy for the treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer.